Covance reported that Barry J. Goldstein, MD, PhD, has joined its clinical development services business as vice-president and global therapeutic area head of the expanded cardiovascular, metabolic, endocrine, and renal unit. In this new role, Goldstein will join the medical & scientific affairs leadership team and will be based in Princeton, NJ.
Goldstein joins Covance from Merck where he served as vice-president in clinical research and therapeutic area head for diabetes and endocrinology, since 2008. In this role, he managed Merck’s Phase II-IV clinical development team for a large portfolio including diabetes, obesity, osteoporosis, and women’s health. His responsibilities included strategic input to proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, responses to payer inquiries, lifecycle management activities, as well as pharmacovigilance and post-marketing studies. In addition to his biopharmaceutical industry experience, Goldstein’s medical career includes serving as director, division of endocrinology, diabetes & metabolic diseases, Jefferson Medical College at Thomas Jefferson University in Philadelphia from 1992 to 2008. His most recent academic roles include professor of medicine, biochemistry and molecular pharmacology at Jefferson from 1997 to 2008.